The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Metastatic bone disease: Pathogenesis and therapeutic options
Open accessAbstract
Bone metastases (BM) are a common complication of cancer, whose management often requires a multidisciplinary approach. Despite the recent therapeutic advances, patients with BM may still experience skeletal-related events and symptomatic skeletal events, with detrimental impact on quality of life and survival. A deeper knowledge of the mechanisms underlying the onset of lytic and sclerotic BM has been acquired in the last decades, leading to the development of bone-targeting agents (BTA), mainly represented by anti-resorptive drugs and bone-seeking radiopharmaceuticals. Recent pre-clinical and clinical studies have showed promising effects of novel agents, whose safety and efficacy need to be confirmed by prospective clinical trials. Among BTA, adjuvant bisphosphonates have also been shown to reduce the risk of BM in selected breast cancer patients, but failed to reduce the incidence of BM from lung and prostate cancer. Moreover, adjuvant denosumab did not improve BM free survival in patients with breast cancer, suggesting the need for further investigation to clarify BTA role in early-stage malignancies. The aim of this review is to describe BM pathogenesis and current treatment options in different clinical settings, as well as to explore the mechanism of action of novel potential therapeutic agents for which further investigation is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
Self-citationAbiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
Coleman, R. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0931 · Cited by 2,488
Self-citationBonewald, L. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.320 · Cited by 2,287
Drug delivery with carbon nanotubes for in vivo cancer treatment
Liu, Z., Chen, K., Davis, C. R., Sherlock, S. P., Cao, Q., Chen, X. S., & Dai, H. (2008) · PubMed · doi:10.48550/arxiv.0808.2070 · Cited by 2,286
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 1,978
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Self-citationRomosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
Stopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,597
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Zheng, M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh141 · Cited by 1,201
Choueiri, T. K., Escudier, B., Powles, T., Tannir, N. M., Mainwaring, P. N., Rini, B. I., Hammers, H. J., Donskov, F., Roth, B. J., Peltola, K., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30107-3 · Cited by 958
Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M., Coleman, R. E., Reitsma, D. J., et al. (2001) · PubMed · Cited by 896
Self-citationRosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., et al. (2003) · Cancer · doi:10.1002/cncr.11701 · Cited by 873
Self-citationDimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00464-7 · Cited by 857
Randomized Trial of Short- Versus Long-Course Radiotherapy for Palliation of Painful Bone Metastases
Hartsell, W. F., Scott, C. B., Bruner, D. W., Scarantino, C. W., Ivker, R. A., Roach, M., Suh, J. H., Demas, W. F., Movsas, B., Petersen, I. A., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji139 · Cited by 823
Smith, M. R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., Miller, K., Sieber, P., Karsh, L., Damião, R., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61226-9 · Cited by 797
Self-citationMacedo, F., Ladeira, K., Pinho, F., Saraiva, N., Bonito, N., Pinto, L., & Gonçalves, F. (2017) · Oncology Reviews · doi:10.4081/oncol.2017.321 · Cited by 775
EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition
中川, 学. (2014) · Institutional Repositories DataBase (IRDB) · Cited by 736
Rosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., et al. (2004) · Cancer · doi:10.1002/cncr.20308 · Cited by 705
Steenland, E., Leer, J., van Houwelingen, H., Post, W. J., van den Hout, W. B., Kievit, J., de Haes, H., Martijn, H., Oei, B., Vonk, E., et al. (1999) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(99)00110-3 · Cited by 677
Bellido, T., Ali, A. A., Gubrij, I., Plotkin, L. I., Fu, Q., O’Brien, C. A., Manolagas, S. C., & Jilka, R. L. (2005) · Endocrinology · doi:10.1210/en.2005-0239 · Cited by 641
Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate
Nelson, J. B., Hedican, S. P., George, D. J., Reddi, A. H., Piantadosi, S., Eisenberger, M. A., & Simons, J. W. (1995) · Nature Medicine · doi:10.1038/nm0995-944 · Cited by 622
Bone health in cancer patients: ESMO Clinical Practice Guidelines
Coleman, R., Body, J. J., Aapro, M., Hadji, P., & Herrstedt, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu103 · Cited by 564
Self-citationYardley, D. A., Noguchi, S., Pritchard, K. I., Burris, H. A., Baselga, J., Gnant, M., Hortobagyi, G. N., Campone, M., Pistilli, B., Piccart, M., et al. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0060-1 · Cited by 522
Tsourdi, E., Langdahl, B., Cohen-Solal, M., Aubry-Rozier, B., Eriksen, E. F., Guañabens, N., Obermayer-Pietsch, B., Ralston, S. H., Eastell, R., & Zillikens, M. C. (2017) · Bone · doi:10.1016/j.bone.2017.08.003 · Cited by 504
Raje, N., Terpos, E., Willenbacher, W., Shimizu, K., García-Sanz, R., Durie, B., Legieć, W., Krejčí, M., Laribi, K., Zhu, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30072-x · Cited by 449
Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone
Kobayashi, A., Okuda, H., Xing, F., Pandey, P. R., Watabe, M., Hirota, S., Pai, S. K., Liu, W., Fukuda, K., Chambers, C., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110840 · Cited by 427
Beer, T. M., Armstrong, A. J., Rathkopf, D., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Evans, C. P., Kim, C.-S., Kimura, G., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.07.032 · Cited by 424
The pre-metastatic niche: finding common ground
Sceneay, J., Smyth, M. J., & Möller, A. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9420-1 · Cited by 422
Vahle, J. L., Long, G. G., Sandusky, G., Westmore, M., Ma, Y. L., & Sato, M. (2004) · Toxicologic Pathology · doi:10.1080/01926230490462138 · Cited by 376
Himelstein, A. L., Foster, J. C., Khatcheressian, J. L., Roberts, J. D., Seisler, D. K., Novotny, P. J., Qin, R., Go, R. S., Grubbs, S. S., O’Connor, T., et al. (2017) · JAMA · doi:10.1001/jama.2016.19425 · Cited by 356
Pathogenesis of bone disease in multiple myeloma: from bench to bedside
Terpos, E., Ntanasis-Stathopoulos, I., Gavriatopoulou, M., & Dimopoulos, M. A. (2018) · Blood Cancer Journal · doi:10.1038/s41408-017-0037-4 · Cited by 354
Trends in overall survival and costs of multiple myeloma, 2000–2014
Fonseca, R., Abouzaid, S., Bonafede, M., Cai, Q., Parikh, K., Cosler, L., & Richardson, P. (2017) · Leukemia · doi:10.1038/leu.2016.380 · Cited by 323
Shiozawa, Y., Pedersen, E. A., Patel, L. R., Ziegler, A. M., Havens, A. M., Jung, Y., Wang, J., Zalucha, S., Loberg, R. D., Pienta, K. J., et al. (2010) · Neoplasia · doi:10.1593/neo.91384 · Cited by 314
Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Knauer, M., Moik, M., Jakesz, R., Seifert, M., Taucher, S., Bjelic-Radisic, V., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu544 · Cited by 312
Hurvitz, S. A., Andre, F., Jiang, Z., Shao, Z., Mano, M. S., Neciosup, S. P., Tseng, L.-M., Zhang, Q., Shen, K., Liu, D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00051-0 · Cited by 306
Coleman, R., Cameron, D., Dodwell, D., Bell, R., Wilson, C., Rathbone, E., Keane, M., Gil, M., Burkinshaw, R., Grieve, R., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70302-x · Cited by 300
Self-citationRecker, R. R., Benson, C. T., Matsumoto, T., Bolognese, M. A., Robins, D. A., Alam, J., Chiang, A. Y., Hu, L., Krege, J. H., Sowa, H., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2351 · Cited by 293
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair
Florio, M., Gunasekaran, K., Stolina, M., Li, X., Liu, L., Tipton, B., Salimi-Moosavi, H., Asuncion, F. J., Li, C., Sun, B., et al. (2016) · Nature Communications · doi:10.1038/ncomms11505 · Cited by 257
Macedo, F. (2017) · Cancer therapy & Oncology International Journal · doi:10.19080/ctoij.2017.04.555637 · Cited by 257
Smith, M. R., Halabi, S., Ryan, C. J., Hussain, A., Vogelzang, N., Stadler, W., Hauke, R. J., Monk, J. P., Saylor, P., Bhoopalam, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.6500 · Cited by 251
Smith, M., De Bono, J., Sternberg, C., Le Moulec, S., Oudard, S., De Giorgi, U., Krainer, M., Bergman, A., Hoelzer, W., De Wit, R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5597 · Cited by 249
Dhesy-Thind, S., Fletcher, G. G., Blanchette, P. S., Clemons, M. J., Dillmon, M. S., Frank, E. S., Gandhi, S., Gupta, R., Mates, M., Moy, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7257 · Cited by 222
Delgado-Calle, J., Anderson, J., Cregor, M. D., Hiasa, M., Chirgwin, J. M., Carlesso, N., Yoneda, T., Mohammad, K. S., Plotkin, L. I., Roodman, G. D., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1703 · Cited by 214
Hadji, P., Coleman, R. E., Wilson, C., Powles, T. J., Clézardin, P., Aapro, M., Costa, L., Body, J.-J., Markopoulos, C., Santini, D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv617 · Cited by 207
Self-citationA Cathepsin K Inhibitor Reduces Breast Cancer–Induced Osteolysis and Skeletal Tumor Burden
Le Gall, C., Bellahcène, A., Bonnelye, E., Gasser, J. A., Castronovo, V., Green, J., Zimmermann, J., & Clézardin, P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3940 · Cited by 204
Foro Arnalot, P., Fontanals, A. V., Galcerán, J. C., Lynd, F., Latiesas, X. S., de Dios, N. R., Castillejo, A. R., Bassols, M. L., Galán, J. L., Conejo, I. M., et al. (2008) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.05.018 · Cited by 203
Bisphosphonates: Molecular Mechanisms of Action and Effects on Bone Cells, Monocytes and Macrophages
J. Roelofs, A., Thompson, K., H. Ebetino, F., J. Rogers, M., & P. Coxon, F. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210793563635 · Cited by 202
Paterson, A. H., Anderson, S. J., Lembersky, B. C., Fehrenbacher, L., Falkson, C. I., King, K. M., Weir, L. M., Brufsky, A. M., Dakhil, S., Lad, T., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70226-7 · Cited by 194
McDonald, M. M., Reagan, M. R., Youlten, S. E., Mohanty, S. T., Seckinger, A., Terry, R. L., Pettitt, J. A., Simic, M. K., Cheng, T. L., Morse, A., et al. (2017) · Blood · doi:10.1182/blood-2017-03-773341 · Cited by 185
Terpos, E., Christoulas, D., Katodritou, E., Bratengeier, C., Gkotzamanidou, M., Michalis, E., Delimpasi, S., Pouli, A., Meletis, J., Kastritis, E., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27342 · Cited by 184
Increased Dickkopf-1 expression in breast cancer bone metastases
Voorzanger-Rousselot, N., Goehrig, D., Journe, F., Doriath, V, Body, J. J., Clézardin, P., & Garnero, P. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603959 · Cited by 174
Iyer, S. P., Beck, J. T., Stewart, A. K., Shah, J. J., Kelly, K. R., ISAACS, R. E., Bilic, S., Sen, S., & Munshi, N. C. (2014) · British Journal of Haematology · doi:10.1111/bjh.13056 · Cited by 172
Morgan, G. J., Davies, F. E., Gregory, W. M., Bell, S. E., Szubert, A. J., Cook, G., Drayson, M. T., Owen, R. G., Ross, F. M., Jackson, G. H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3211 · Cited by 167
Junankar, S. R., Shay, G., Jurczyluk, J., Ali, N., Down, J. M., POCOCK, N. A., Parker, A., Nguyen, A., Sun, S., Kashemirov, B. A., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0621 · Cited by 165
Hortobagyi, G. N., Van Poznak, C., Harker, W. G., Gradishar, W. J., Chew, H., Dakhil, S. R., Haley, B. B., Sauter, N., Mohanlal, R., Zheng, M., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6316 · Cited by 164
Jensen, A. B., Wynne, C. J., Ramírez, G., He, W., Song, Y., Berd, Y., Wang, H., Mehta, A., & Lombardi, A. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.059 · Cited by 158
Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials
Gdowski, A., Ranjan, A. P., & Vishwanatha, J. K. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0578-1 · Cited by 151
Chantry, A., Heath, D., Mulivor, A. W., Pearsall, S., Baud’huin, M., Coulton, L. A., Evans, H., Abdul, N., Werner, E. D., Bouxsein, M., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.142 · Cited by 147
Bone, H. G., Dempster, D., Eisman, J. A., Greenspan, S. L., McClung, M. R., Nakamura, T., Papapoulos, S. E., Shih, W. J., Rybak-Feiglin, A., Santora, A. C., et al. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2944-6 · Cited by 147
Rucci, N., Recchia, I., Angelucci, A., Alamanou, M., Fattore, A. D., Fortunati, D., Šuša, M., Fabbro, D., Bologna, M., & Teti, A. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.102004 · Cited by 141
Wirth, M. P., Tammela, T. L. J., Cicalese, V., Veiga, F. G., Delaere, K. P. J., Miller, K., Tubaro, A., Schulze, M., Debruyne, F. M. J., Huland, H., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.02.014 · Cited by 130
Sotatercept in patients with osteolytic lesions of multiple myeloma
Km, A., Salogub, G., Khuazheva, N. K., Sherman, M. L., Laadem, A., Barger, R., Knight, R., Srinivasan, S. S., & Terpos, E. (2014) · British Journal of Haematology · doi:10.1111/bjh.12835 · Cited by 129
Accardi, F., Toscani, D., Bolzoni, M., Palma, B. D., Aversa, F., & Giuliani, N. (2015) · BioMed Research International · doi:10.1155/2015/172458 · Cited by 126
Cancer Cell Colonisation in the Bone Microenvironment
Kan, C. W. S., Vargas, G., Pape, F. L., & Clézardin, P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101674 · Cited by 126
Saidak, Z., Boudot, C., Abdoune, R., Petit, L., Brazier, M., Mentaverri, R., & Kamel, S. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.03.003 · Cited by 125
CXCL10 Promotes Osteolytic Bone Metastasis by Enhancing Cancer Outgrowth and Osteoclastogenesis
Lee, J.-H., Kim, H., Kim, K.-O., Jin, W. J., Lee, S., Kim, H.-H., Ha, H., & Lee, Z. H. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0481 · Cited by 125
Bone-Targeted Therapies in Cancer-Induced Bone Disease
Sousa, S., & Clézardin, P. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0353-5 · Cited by 125
The rejuvenated scenario of epithelial–mesenchymal transition (EMT) and cancer metastasis
Meng, F., & Wu, G. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9379-3 · Cited by 124
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer
Leto, G., Incorvaia, L., Badalamenti, G., Tumminello, F. M., Gebbia, N., Flandina, C., Crescimanno, M., & Rini, G. (2006) · Clinical & Experimental Metastasis · doi:10.1007/s10585-006-9010-5 · Cited by 117
Parker, C. C., Coleman, R. E., Sartor, O. A., Vogelzang, N. J., Bottomley, D., Heinrich, D. A., Helle, S. I., O’Sullivan, J. M., Fosså, S. D., Chodacki, A., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.06.021 · Cited by 115
Self-citationCampone, M., Bondarenko, I., Brincat, S., Hotko, Y., Munster, P. N., Chmielowska, E., Fumoleau, P., Ward, R. L., Bardy‐Bouxin, N., Leip, E. P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr261 · Cited by 114
Lipton, A., Fizazi, K. S., Stopeck, A., Henry, D. H., Smith, M. R., Shore, N. D., Martín, M., Vadhan‐Raj, S., Brown, J. E., Richardson, G. E., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.011 · Cited by 113
Self-citationTerpos, E., Kastritis, E., Christoulas, D., Gkotzamanidou, M. A., Eleutherakis‐Papaiakovou, E., Kanellias, N., Παπαθεοδώρου, Α., & Dimopoulos, M. A. (2012) · Annals of Oncology · doi:10.1093/annonc/mds068 · Cited by 109
The role of biomarkers in the management of bone-homing malignancies
D’Oronzo, S., Brown, J. E., & Coleman, R. E. (2017) · Journal of bone oncology · doi:10.1016/j.jbo.2017.09.001 · Cited by 108
Self-citationTaylor, S., Ominsky, M. S., Hu, R., Pacheco, E., He, Y. D., Brown, D. L., Aguirre, J. I., Wronski, T. J., Buntich, S., Afshari, C. A., et al. (2016) · Bone · doi:10.1016/j.bone.2015.12.013 · Cited by 106
Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2
Gnant, M., Baselga, J. M., Rugo, H. S., Noguchi, S., Burris, H. A., Piccart, M. J., Hortobágyi, G. N., Eakle, J. F., Mukai, H., Iwata, H., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt026 · Cited by 105
Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer
Lin, S.-C., Lee, Y.-C., Yu, G., Cheng, C., Zhou, X., Chu, K., Murshed, M., Baseler, L. J., Baseler, L., Abe, J., et al. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.05.005 · Cited by 105
Eda, H., Santo, L., Wein, M. N., Hu, D. Z., Cirstea, D. D., Nemani, N., Tai, Y., Raines, S. E., Kuhstoss, S. A., Munshi, N. C., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2789 · Cited by 103
Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity
Kitagawa, Y., Dai, J., Zhang, J., Keller, J. M., Nor, J., Yao, Z., & Keller, E. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1809 · Cited by 101
Coluccia, A. M. L., Cirulli, T., Neri, P. E., Mangieri, D., Colanardi, M. C., Gnoni, A., Renzo, N. D., Dammacco, F., Tassone, P., Ribatti, D., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116590 · Cited by 101
Yu, E. Y., Massard, C., Gross, M. E., Carducci, M. A., Culine, S., Hudes, G. R., Posadas, E. M., Sternberg, C. N., Wilding, G., Trudel, G. C., et al. (2011) · Urology · doi:10.1016/j.urology.2011.01.006 · Cited by 90
Dedes, P. G., Gialeli, C., Tsonis, A., Kanakis, I., Theocharis, A. D., Kletsas, D., Tzanakakis, G. N., & Karamanos, N. K. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.07.013 · Cited by 84
Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease
García-Gómez, A., Quwaider, D., Canavese, M., Ocio, E. M., Tian, Z., Blanco, J. F., Berger, A., Ortíz-de-Solórzano, C., Hernández‐Iglesias, T., Martens, A. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1657 · Cited by 84
Antonarakis, E. S., Heath, E. I., Posadas, E. M., Yu, E. Y., Harrison, M. R., Bruce, J. Y., Cho, S. Y., Wilding, G. E., Fetterly, G. J., Hangauer, D. G., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2079-z · Cited by 77
Raftopoulos, H., Laadem, A., Hesketh, P. J., Goldschmidt, J. H., Gabrail, N. Y., Osborne, C. R. C., Ali, M., Sherman, M. L., Wang, D., Glaspy, J. A., et al. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2929-9 · Cited by 73
Surgical treatment of bone metastasis: indications and outcomes
Manabe, J., Kawaguchi, N., Matsumoto, S., et al. (2004) · International Journal of Clinical Oncology · doi:10.1007/s10147-005-0478-9 · Cited by 72
Nguyen, H. M., Ruppender, N. S., Zhang, X., Brown, L. G., Gross, T. S., Morrissey, C. M., Gulati, R., Vessella, R. L., Schimmöller, F., Aftab, D. T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078881 · Cited by 70
Cabillic, F., Toutirais, O., Lavoué, V., Pintière, C. T. D. L., Daniel, P., Rioux-Leclercq, N. C., Turlin, B., Mönkkönen, H., Mönkkönen, J., Boudjéma, K., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0887-0 · Cited by 70
Schott, A. F., Barlow, W. E., Poznak, C. H. V., Hayes, D. F., Moinpour, C. M., Lew, D. L., Dy, P. A., Keller, E. T., Keller, J. M., & Hortobágyi, G. N. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3911-z · Cited by 70
Coleman, R. E., Finkelstein, D. M., Barrios, C. H., Martín, M., Iwata, H., Glaspy, J. A., Zhou, Y. Y., Jandial, D., & Chan, A. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.501 · Cited by 70
Self-citationHortobágyi, G. N. (2015) · Neoplasia · doi:10.1016/j.neo.2015.01.005 · Cited by 69
Kang, H., Huang, H.-Y., Hsieh, C., Li, C., Shyr, C., Tsai, M., Chang, C., Chuang, Y., & Huang, K. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090219 · Cited by 63
Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases
Hussein, O., Tiedemann, K., Murshed, M., & Komarova, S. V. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.026 · Cited by 56
Iuliani, M., Pantano, F., Buttigliero, C., Fioramonti, M., Bertaglia, V., Vincenzi, B., Zoccoli, A., Ribelli, G., Tucci, M., Vignani, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3724 · Cited by 55
Tucci, M., Stucci, L. S., Savonarola, A., Ciavarella, S., Cafforio, P., Dammacco, F., & Silvestris, F. (2013) · British Journal of Haematology · doi:10.1111/bjh.12333 · Cited by 55
Self-citationPennisi, A., Ling, W., Li, X., Khan, S., Wang, Y., Barlogie, B., Shaughnessy, J. D., & Yaccoby, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015233 · Cited by 54
Prevention of breast cancer skeletal metastases with parathyroid hormone
Swami, S., Johnson, J., Bettinson, L. A., Kimura, T., Zhu, H., Albertelli, M. A., Johnson, R. W., & Wu, J. Y. (2017) · JCI Insight · doi:10.1172/jci.insight.90874 · Cited by 54
Myeloma bone disease: Pathogenetic mechanisms and clinical assessment
Silvestris, F., Lombardi, L., Matteo, M. D., Bruno, A., & Dammacco, F. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.04.014 · Cited by 53
Self-citationClinical significance of CXCL16/CXCR6�expression in patients with prostate cancer
Ha, H. K. (2011) · Molecular Medicine Reports · doi:10.3892/mmr.2011.446 · Cited by 52
The value of biomarkers in bone metastasis
D’Oronzo, S., Brown, J. E., & Coleman, R. E. (2017) · European Journal of Cancer Care · doi:10.1111/ecc.12725 · Cited by 50
Self-citationMitri, Z. I., Nanda, R., Blackwell, K., Costelloe, C. M., Hood, I., Wei, C., Brewster, A. M., Ibrahim, N. K., Koenig, K. B., Hortobágyi, G. N., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2845 · Cited by 45
Scullen, T. A., Santo, L., Vallet, S., Fulciniti, M., Eda, H., Cirstea, D. D., Patel, K. J., Nemani, N., Yee, A. J., Mahindra, A. K., et al. (2013) · Leukemia · doi:10.1038/leu.2013.50 · Cited by 44
Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells
Ubellacker, J. M., Haider, M., DeCristo, M. J., Allocca, G., Brown, N. J., Silver, D. P., Holen, I., & McAllister, S. S. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0815-8 · Cited by 43
Yee, A. J., Hari, P., Marcheselli, R., Mahindra, A. K., Cirstea, D. D., Scullen, T. A., Burke, J. N., Rodig, S. J., Hideshima, T., Laubach, J. P., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12909 · Cited by 42
Wang, X., He, Y., Zhou, S., Jiang, J.-Z., Huang, Y., Liang, Y., & Lai, Y.-R. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.02.010 · Cited by 42
Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study
Gunther, A., Baumann, P., Burger, R., Kellner, C., Klapper, W., Schmidmaier, R., & Gramatzki, M. (2015) · Haematologica · doi:10.3324/haematol.2014.116269 · Cited by 42
Effects of Src-kinase inhibition in cancer-induced bone pain
Felice, M. D., Lambert, D., Holen, I., Escott, K. J., & Andrew, D. (2016) · Molecular Pain · doi:10.1177/1744806916643725 · Cited by 41
Munshi, N. C., Abonour, R., Beck, J. T., et al. (2012) · Blood · doi:10.1182/blood.v120.21.331.331 · Cited by 41
135 CLINICAL SIGNIFICANCE OF CXCL16/CXCR6 EXPRESSION IN PATIENTS WITH PROSTATE CANCER
Kim, H. W., Ha, H. K., Lee, W., Park, E., Shin, D. G., Lee, J. Z., & Chung, M. K. (2011) · The Journal of Urology · doi:10.1016/j.juro.2011.02.202 · Cited by 38
Vaishampayan, U. N., Shevrin, D. H., Stein, M. N., Heilbrun, L. K., Land, S. J., Stark, K., Li, J., Dickow, B., Heath, E. I., Smith, D. W., et al. (2015) · Urology · doi:10.1016/j.urology.2015.08.008 · Cited by 37
Bone-Resorbing Cells in Multiple Myeloma: Osteoclasts, Myeloma Cell Polykaryons, or Both?
Silvestris, F., Ciavarella, S., Matteo, M. D., Tucci, M., & Dammacco, F. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0087 · Cited by 33
Self-citationTherapeutic approaches to myeloma bone disease: An evolving story
Longo, V., Brunetti, O., D’Oronzo, S., Dammacco, F., & Silvestris, F. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.03.004 · Cited by 27
Self-citationHutton, B., Addison, C., Campbell, K., Fergusson, D. A., Mazzarello, S., & Clemons, M. J. (2013) · Journal of bone oncology · doi:10.1016/j.jbo.2013.05.001 · Cited by 25
Turner, P. G., & O’Sullivan, J. M. (2015) · British Journal of Radiology · doi:10.1259/bjr.20140752 · Cited by 23
Endothelin-A receptor antagonists in prostate cancer treatment-a meta-analysis.
Qiao, L., Liang, Y., Li, N., Hu, X., Luo, D., Gu, J., Lu, Y., & Zheng, Q. (2015) · Europe PMC (PubMed Central) · Cited by 23
Rizzo, S., Galvano, A., Pantano, F., Iuliani, M., Vincenzi, B., Passiglia, F., Spoto, S., Tonini, G., Bazan, V., Russo, A. G., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.09.008 · Cited by 19
Sezer, O., Beksaç, M., Hájek, R., Sucak, G. T., Çağırgan, S., Linkesch, W., Akay, O. M., Gülbaş, Z., Nahi, H., Plesner, T., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14637 · Cited by 16
Cafforio, P., D’Oronzo, S., Felici, C., Sigala, S., Fragni, M., & Silvestris, F. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.06.023 · Cited by 13
Self-citationYu, Y., Song, Z., Yang, S., Yang, X., Zhang, J., & Lü, S. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmu069 · Cited by 12
Cited by
Bone health in cancer: ESMO Clinical Practice Guidelines
Coleman, R., Hadji, P., Body, J.-J., Santini, D., Chow, E., Terpos, E., Oudard, S., Bruland, Ø., Flamen, P., Kurth, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.019 · Cited by 549
Self-citationExtracellular Matrix Alterations in Metastatic Processes
Paolillo, M., & Schinelli, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194947 · Cited by 377
The Regulation of Bone Metabolism and Disorders by Wnt Signaling
Maeda, K., Kobayashi, Y., Koide, M., Uehara, S., Okamoto, M., Ishihara, A., Kayama, T., Saito, M., & Marumo, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225525 · Cited by 353
Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives
Zöllner, S. K., Amatruda, J. F., Bauer, S., Collaud, S., de Álava, E., DuBois, S. G., Hardes, J., Hartmann, W., Kovar, H., Metzler, M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081685 · Cited by 271
Vlashi, R., Zhang, X., Wu, M., & Chen, G. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.011 · Cited by 165
Metadata
- Authors
- D'Oronzo, S., Coleman, R., Brown, J., & Silvestris, F.
- Venue
- Journal of Bone Oncology
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 15
- Pages
- 100205
- ISSN
- 2212-1366 (ISSN-L)
- 2212-1374
- OpenAlex
- W2899834008
- Cited by
- 255
- References
- 126
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.